Venetoclax
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Using no additional skill — this is a direct data-to-report transformation task per the fixed template; brainstorming/systematic-debugging don't apply here.
Venetoclax: From Chronic Lymphocytic Leukemia to Pregerminal Center CLL/SLL
One-Sentence Summary
Venetoclax is a selective, orally available BCL-2 inhibitor whose established use in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) is documented within the supporting literature of this evidence pack. The TxGNN model predicts a signal for pregerminal center CLL/SLL — an IGHV-unmutated, poor-prognosis molecular subtype of CLL/SLL — but this specific subgroup currently has 0 dedicated clinical trials and only 1 supporting publication, marking it as an early, hypothesis-generating signal rather than a validated new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic Lymphocytic Leukemia (CLL) — per embedded literature evidence (e.g., PMID 28724540, 33230098) |
| Predicted New Indication | Pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma |
| TxGNN Prediction Score | 99.55% |
| Evidence Level | L4 |
| Norway Market Status | ✗ Not Marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Venetoclax selectively inhibits BCL-2, a pro-survival protein that is overexpressed in most B-cell malignancies, thereby restoring the intrinsic (mitochondrial) apoptotic pathway and triggering tumor cell death. This mechanism is well documented across the pack's literature evidence (e.g., PMID 28724540: "a highly potent and selective oral BCL-2 antagonist… approved in chronic lymphocytic leukemia"; PMID 33230098: FDA-approved for AML in combination with hypomethylating agents). A formal, structured MOA record from DrugBank was not retrievable for this candidate (data gap DG002, High severity).
The predicted "new" indication is not a distinct disease but a refined molecular subtype within CLL/SLL itself — specifically the IGHV-unmutated (U-CLL), pre-germinal-center-origin subgroup, historically associated with poorer prognosis compared to the mutated (M-CLL, post-germinal-center) subtype captured separately at rank 2. Since BCL-2 dependency is a pathogenic hallmark of CLL regardless of IGHV mutation status, the mechanistic rationale for venetoclax activity plausibly extends to this subgroup.
However, the single supporting reference (PMID 35158929, a 2022 review on B-cell receptor structure/function in CLL) only characterizes the biological distinction between U-CLL and M-CLL — it does not report venetoclax outcomes stratified by this subtype. No dedicated clinical trial isolates this molecular subgroup, so the prediction should be read as a biologically plausible refinement of venetoclax's already-established CLL indication, not as independent proof of efficacy in a new disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35158929 | 2022 | Review | Cancers | Characterizes the pre-germinal center (U-IGHV, poor prognosis) vs. post-germinal center (M-IGHV, good prognosis) CLL subsets and their B-cell receptor structure/function differences; does not report venetoclax-specific outcomes. |
Norway Market Information
No marketing authorization records are available for Venetoclax in this evidence pack — the drug is currently not marketed (0 licenses on file).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (selective BCL-2 inhibitor; not a conventional cytotoxic chemotherapeutic) |
| Myelosuppression Risk | High — literature within this pack reports thrombocytopenia in up to 80% of patients in combination regimens (PMID 38264906) and identifies tumor lysis syndrome and myelosuppression as the most common toxicities of venetoclax-based therapy (PMID 35659041) |
| Emetogenicity Classification | Low to Moderate (consistent with the oral targeted BCL-2 inhibitor class; not separately quantified in this evidence pack) |
| Monitoring Items | CBC with differential (neutropenia/thrombocytopenia), tumor lysis syndrome labs during dose ramp-up (potassium, uric acid, calcium, phosphate, creatinine), liver function |
| Handling Protection | Standard hazardous/antineoplastic drug handling precautions recommended for pharmacy compounding and dispensing, consistent with its classification as an antineoplastic agent |
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not retrievable in this evidence pack (TFDA label retrieval flagged as a Blocking data gap, DG001).
Conclusion and Next Steps
Decision: Research Question
Rationale: The BCL-2-dependency mechanism underlying venetoclax's established CLL activity is biologically plausible for this IGHV-unmutated subtype, but the complete absence of dedicated clinical trials and reliance on a single non-specific review article means the evidence does not yet support progression beyond a research hypothesis. (For context, other predicted indications in this pack — e.g., myeloid leukemia, evidence level L1 — already have Phase 3-supported, guideline-aligned venetoclax regimens and may warrant separate, higher-priority review.)
To proceed, the following is needed:
- TFDA/regulatory label data (warnings, contraindications) — currently a Blocking gap
- Structured mechanism-of-action documentation from DrugBank
- A clinical trial or retrospective cohort stratifying venetoclax outcomes specifically by IGHV mutation status in CLL/SLL
- Safety monitoring plan addressing myelosuppression and tumor lysis syndrome risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.